Accelerate Diagnostics (MEX:AXDX) Beneish M-Score: 0.00 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AXDX Accelerate Diagnostics Inc MEX:AXDX
12 GF Score
Price MXN1.75
View Full Analysis

What is Accelerate Diagnostics Beneish M-Score?

Accelerate Diagnostics MEX:AXDX 12 Beneish M-Score is 0.00 as of Sep. 09, 2026. GuruFocus rates MEX:AXDX with a GF Score™ of 12/100.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Accelerate Diagnostics's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Accelerate Diagnostics was 0.00. The lowest was 0.00. And the median was 0.00.

Accelerate Diagnostics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Accelerate Diagnostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accelerate Diagnostics Beneish M-Score Chart

Accelerate Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.11 -9.74 -4.38 -4.86 -6.70

Accelerate Diagnostics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.86 -5.37 -6.11 -5.70 -6.70

MEX:AXDX vs MSIU, BIOLQ, AFIB: Beneish M-Score Comparison

For the Medical Devices subindustry, Accelerate Diagnostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerate Diagnostics Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's Beneish M-Score falls into.


MEX:AXDX
12GF Score
Accelerate Diagnostics Inc MEX:AXDX
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accelerate Diagnostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Accelerate Diagnostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9074+0.528 * 0.9257+0.404 * 0.3024+0.892 * 1.0519+0.115 * 1.1416
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6978+4.679 * -0.76109-0.327 * 1.8088
=-6.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was MXN42.5 Mil.
Revenue was 58.73 + 58.579 + 54.704 + 48.478 = MXN220.5 Mil.
Gross Profit was 9.364 + 16.855 + 12.384 + 11.999 = MXN50.6 Mil.
Total Current Assets was MXN463.8 Mil.
Total Assets was MXN595.6 Mil.
Property, Plant and Equipment(Net PPE) was MXN121.3 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN64.4 Mil.
Selling, General, & Admin. Expense(SGA) was MXN400.3 Mil.
Total Current Liabilities was MXN650.7 Mil.
Long-Term Debt & Capital Lease Obligation was MXN1,031.0 Mil.
Net Income was -199.985 + -288.246 + -212.293 + -236.165 = MXN-936.7 Mil.
Non Operating Income was 53.265 + -51.333 + -9.325 + -30.272 = MXN-37.7 Mil.
Cash Flow from Operations was -105.697 + -60.863 + -138.921 + -140.272 = MXN-445.8 Mil.
 Total Receivables was MXN44.5 Mil.
Revenue was 51.381 + 57.465 + 50.077 + 50.686 = MXN209.6 Mil.
Gross Profit was 10.745 + 1.864 + 13.698 + 18.223 = MXN44.5 Mil.
Total Current Assets was MXN415.3 Mil.
Total Assets was MXN532.4 Mil.
Property, Plant and Equipment(Net PPE) was MXN86.3 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN56.6 Mil.
Selling, General, & Admin. Expense(SGA) was MXN545.3 Mil.
Total Current Liabilities was MXN204.3 Mil.
Long-Term Debt & Capital Lease Obligation was MXN626.9 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(42.483 / 220.491) / (44.506 / 209.609)
=0.192675 / 0.212329
=0.9074

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(44.53 / 209.609) / (50.602 / 220.491)
=0.212443 / 0.229497
=0.9257

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (463.789 + 121.338) / 595.555) / (1 - (415.292 + 86.297) / 532.414)
=0.01751 / 0.057897
=0.3024

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=220.491 / 209.609
=1.0519

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(56.578 / (56.578 + 86.297)) / (64.446 / (64.446 + 121.338))
=0.395997 / 0.346887
=1.1416

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(400.299 / 220.491) / (545.339 / 209.609)
=1.815489 / 2.601696
=0.6978

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1031.043 + 650.719) / 595.555) / ((626.927 + 204.268) / 532.414)
=2.823857 / 1.561182
=1.8088

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-936.689 - -37.665 - -445.753) / 595.555
=-0.76109

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Accelerate Diagnostics has a M-score of -6.60 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Accelerate Diagnostics (MEX:AXDX) has a Beneish M-Score of 0.00 as of Sep. 09, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Beneish M-Score too high?
Accelerate Diagnostics' current Beneish M-Score is 0.00. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Beneish M-Score compare to MSIU and BIOLQ?
Accelerate Diagnostics' Beneish M-Score of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Accelerate Diagnostics and its competitors. Accelerate Diagnostics's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Beneish M-Score is 0.00 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accelerate Diagnostics Business Description

Address 3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score

Get the complete analysis for MEX:AXDX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1.75
Price